Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1891-1900 of 3398 for cancer

Edit search filters
  1. Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  2. Study To Evaluate The Efficacy And Safety Of Lutathera In Patients With Grade 2 And Grade 3 Advanced GEP-NET

    Rochester, MN

  3. First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM)

    Rochester, MN

  4. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

    Rochester, MN

  5. Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study Of ASTX660 Alone Or Combined With ASTX727 In Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

    Rochester, MN

  7. Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. An Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

    Jacksonville, FL

  10. A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer